13F filer · 10x Genomics, Inc. · 10X Genomics Inc
TRIM
$65.7M quarter-over-quarter change
Not applicable — 13F reports quarter-end holdings, execution dates are not disclosed
First recorded trade by this actor in this security
1 other actor traded the same direction within 14 days
| Score | Actor | Security | Side | Value | Disclosed | Evidence |
|---|---|---|---|---|---|---|
| 13 | Taich AdamChief Financial Officer | Open-market sale · 10b5-1 plan | SELL |
Read directly from the primary public document; every field below is as reported by the filer.
ARK Investment Management LLC reported this position change in a quarterly 13F holdings report. 13F shows quarter-end positions only — it does not say when during the quarter shares were bought or sold.
No field has changed since this record was first ingested.
No material filings recorded for this issuer.
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
| $77K 1,206 sh |
| Sep 11, 2026 traded Sep 9, 2026 |
| 23 | Taich AdamChief Financial Officer | Open-market sale · 10b5-1 plan | SELL | $2.02M 31.4K sh | Sep 11, 2026 traded Sep 9, 2026 |
| 16 | Taich AdamChief Financial Officer | Open-market sale · 10b5-1 plan | SELL | $898K 13.8K sh | Sep 11, 2026 traded Sep 9, 2026 |
| 18 | Saxonov SergeDirector, Chief Executive Officer | Open-market sale · 10b5-1 plan | SELL | $221K 3,500 sh | Aug 28, 2026 traded Aug 26, 2026 |
| 21 | Saxonov SergeDirector, Chief Executive Officer | Open-market sale · 10b5-1 plan | SELL | $415K 6,494 sh | Aug 28, 2026 traded Aug 26, 2026 |
| 15 | Saxonov SergeDirector, Chief Executive Officer | Open-market sale · 10b5-1 plan | SELL | $32K 492 sh | Aug 28, 2026 traded Aug 26, 2026 |